https://biotechmorning.com/news/otc-naloxone-rextovy-fda-approval Biotech Morning en 2026-06-21T14:18:47.587Z The Overdose Antidote You Can Now Buy Next to the Advil https://biotechmorning.com/news/sarepta-elevidys-gene-therapy-trial-failure-layoffs Biotech Morning en 2026-06-21T14:17:56.471Z The $2.5 Billion Bet on a Gene Therapy That Just Struck Out https://biotechmorning.com/news/astellas-vir-biotechnology-masked-t-cell-engager-deal Biotech Morning en 2026-06-21T14:17:00.099Z Astellas Just Paid $1.7B for a Drug That Plays Dead Until It Finds Cancer https://biotechmorning.com/news/novo-nordisk-vect-horus-delivery-platform-deal Biotech Morning en 2026-06-21T14:16:06.119Z Novo Nordisk Just Paid $327M for a Molecular GPS System https://biotechmorning.com/news/gsk-billion-dollar-bet-hepatitis-b-functional-cure Biotech Morning en 2026-06-21T14:15:12.551Z GSK's Billion-Dollar Bet to Cure a Disease That's Stumped Medicine for Decades https://biotechmorning.com/news/pfizer-obesity-pipeline-monthly-glp1-bet Biotech Morning en 2026-06-20T14:22:21.672Z Pfizer's $10 Billion Bet on a Once-a-Month Weight Loss Shot https://biotechmorning.com/news/novo-nordisk-oral-wegovy-china-filing Biotech Morning en 2026-06-20T14:21:29.363Z Novo Nordisk Wants to Sell a Weight-Loss Pill to 300 Million People https://biotechmorning.com/news/lilly-zepbound-vials-pricing-trick Biotech Morning en 2026-06-20T14:20:36.246Z Lilly's Quiet Trick to Make Zepbound Look Cheap Without Actually Cutting Prices https://biotechmorning.com/news/zepzelca-confirmatory-trial-failure Biotech Morning en 2026-06-20T14:19:45.247Z Zepzelca Just Failed the One Test That Mattered Most https://biotechmorning.com/news/novo-nordisk-cyberattack-fulcrumsec-ransom Biotech Morning en 2026-06-20T14:18:54.798Z Hackers Hit the World's Biggest Pharma Company. Then They Got Greedy. https://biotechmorning.com/news/pharma-300-billion-us-manufacturing-tariff Biotech Morning en 2026-06-20T14:17:55.286Z Big Pharma Is Spending $300 Billion to Avoid a Single Tax https://biotechmorning.com/news/sanofi-riliprubart-cidp-trial-halted Biotech Morning en 2026-06-20T14:17:03.922Z Sanofi's Big Bet on a Rare Nerve Disease Just Hit a Wall https://biotechmorning.com/news/novartis-orionis-molecular-glue-degrader-deal Biotech Morning en 2026-06-20T14:16:13.413Z Novartis Keeps Betting on the Same Tiny Molecule Trick